Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133+ tumor-initiating cell fraction

Stem Cells

Volumn 29, Issue 3, 2011, Pages 418-429

  Gallmeier, Eike ^a   Hermann, Patrick C ^b   Mueller, Maria Theresa ^b   Machado, Juan G ^b   Ziesch, Andreas ^a   De Toni, Enrico N ^a   Palagyi, Andreas ^a   Eisen, Christian ^c   Ellwart, Joachim W ^d   Rivera, Jose ^b   Rubio Viqueira, Belen ^b   Hidalgo, Manuel ^b   Bunz, Fred ^e   Göke, Burkhard ^a   Christopher, Heeschen ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ATR; Cancer stem cells; Colon cancer; DNA damage response; Tumor initiating cells

Indexed keywords

CAFFEINE; CD133 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL CYCLE; CELL FRACTIONATION; COLON CANCER; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SOLID TUMOR;

ANIMALS; ANTIGENS, CD; CARCINOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ATAXIA TELANGIECTASIA; SCHIZOSACCHAROMYCES POMBE;

EID: 79953013766     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.595     Document Type: Article

References (41)

1. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111. (Pubitemid 33041634)
2. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells-An integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-749. (Pubitemid 41486367)
3. Hermann P, Huber S, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323. (Pubitemid 47355323)
4. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
5. Ricci-Vitiani L, Lombardi D, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115. (Pubitemid 46067311)
6. Mueller MT, Hermann PC, Witthauer J et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009;137:1102-1113.
7. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402. (Pubitemid 47506537)
8. Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. Plos One 2008;3:e2428.
9. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008;98:523-528. (Pubitemid 351214533)
10. Ashwell S, Zabludoff S. DNA damage detection and repair pathways - Recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-4037.
11. Bao S, Wu Q, Mclendon R et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
12. Eyler CE, Rich JN. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-2845.
13. Gallmeier E, Calhoun ES, Rago C et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006;130:2145-2154. (Pubitemid 43816948)
14. Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene 2007;26:2535-2542. (Pubitemid 46632006)
15. Jimeno A, Feldmann G, Suarez-Gauthier A et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009;8:310-314.
16. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-10163. (Pubitemid 47175279)
17. Lavrik IN, Golks A, Krammer PH. Caspases: Pharmacological manipulation of cell death. J Clin Invest 2005;115:2665-2672. (Pubitemid 41434390)
18. Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-4382. (Pubitemid 29418757)
19. Hickson I, Zhao Y, Richardson CJ et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9159. (Pubitemid 39665530)
20. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232.
21. Graves PR, Yu L, Schwarz JK et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5605.
22. Ruegg UT, Burgess GM. Staurosporine, K-252 and UCN-01: Potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-220.
23. Busby EC, Leistritz DF, Abraham RT et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-2112. (Pubitemid 30225168)
24. Zhao B, Bower MJ, McDevitt PJ et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002;277:46609-46615. (Pubitemid 35417660)
25. Jackson JR, Gilmartin A, Imburgia C et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60:566-572. (Pubitemid 30094552)
26. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-519.
27. Gallmeier E, Hucl T, Calhoun ES et al. Gene-specific selection against experimental Fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 2007;6:654-660. (Pubitemid 47328343)
28. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004;18:1958-1963. (Pubitemid 39071576)
29. Paulsen RD, Cimprich KA. The ATR pathway: Fine-tuning the fork. DNA Repair (Amst) 2007;6:953-966. (Pubitemid 46880476)
30. Gallmeier E, Kern SE. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: The significance of preclinical pharmacogenomic models. Clin Cancer Res 2007;13:4-10. (Pubitemid 46121846)
31. Cortez D, Guntuku S, Qin J et al. ATR and ATRIP: Partners in checkpoint signaling. Science 2001;294:1713-1716. (Pubitemid 33104841)
32. O'Driscoll M, Ruiz-Perez VL, Woods CG et al. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003;33:497-501. (Pubitemid 36390012)
33. Chen R, Nishimura MC, Bumbaca SM et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer cell 2010;17:362-375.
34. Barker N, Ridgway RA, van Es JH et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-611.
35. Meshorer E, Yellajoshula D, George E et al. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev Cell 2006;10:105-116. (Pubitemid 43025681)
36. Cohn MA, D'Andrea AD. Chromatin recruitment of DNA repair proteins: Lessons from the Fanconi anemia and double-strand break repair pathways. Mol Cell 2008;32:306-312.
37. Murga M, Jaco I, Fan Y et al. Global chromatin compaction limits the strength of the DNA damage response. J Cell Biol 2007;178:1101-1108. (Pubitemid 47480219)
38. Harper JW, Elledge SJ. The DNA damage response: Ten years after. Mol Cell 2007;28:739-745. (Pubitemid 350217064)
39. Nghiem P, Park PK, Kim Y et al. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 2001;98:9092-9097. (Pubitemid 32743874)
40. Collis SJ, Swartz MJ, Nelson WG et al. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-1554. (Pubitemid 36373642)
41. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007;6:1406-1413. (Pubitemid 46712004)